HARMONY BIOSC.HLD.-,00001

Harmony outlines three strategic pillars: expanding the pitolisant franchise with Pitolisant GR (PDUFA April 27) and Pitolisant HD; advancing BP-205 as a potential best-in-class orexin-2 agonist; and developing EPX-100 for rare epilepsies. WAKIX delivered record quarterly sales and funds the pipeline growth, while key milestones are mostly expected in 2027/2028. BP-205 showed strong efficacy, rapid absorption and no relevant safety signals in early studies; EPX-100 demonstrated substantial seizure reductions in Dravet syndrome. The stock closed at $38.50 (-3.19%). » Más en de.investing.com

Harmony Biosciences reported Q1 2026 revenue of $215.4 million, a 17% year-over-year increase driven by continued adoption of WAKIX (pitolisant). Management reaffirmed full-year 2026 net revenue guidance of over $1 billion and highlighted strong operating leverage and cash generation funding its late-stage pipeline. The company is pursuing pediatric narcolepsy approval and exploring indications including idiopathic hypersomnia and Prader-Willi syndrome, supporting investor optimism about lifecycle and pipeline growth. » Más en finance.yahoo.com

Harmony reported Q1 2026 results: WAKIX revenue rose 17% to $215.4 million but missed consensus, and diluted earnings per share fell to $0.55, well below expectations. Management reaffirmed the full-year revenue guidance of $1.0–1.04 billion, attributing the earnings miss to high strategic investments, license costs and increased R&D spending. The company holds about $870.5 million in cash and highlights growth drivers such as enteric-coated and high‑dose pitolisant programs, a broad pipeline and legal actions to defend patents. Despite near-term profitability pressure, Harmony sees a clear path for WAKIX to reach the billion-dollar mark and plans to step up business development transactions. » Más en de.investing.com